Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax?

Moderna’s shares rose 6% on Monday morning, trading near $57.52 after closing at $54.35 on Friday, extending its strong year-to-date gain of 95%. This outperformance surpassed Pfizer, which rose 2% to $26.10, and Novavax, which remained flat near $10.08. The rally was fueled by reports of a cruise ship Hantavirus outbreak, drawing attention to Moderna’s early-stage mRNA-based vaccine research, though the virus’s limited geographic spread reduces near-term commercial demand potential. The stock’s momentum reflects both retail speculation and fundamental strength. Moderna reported Q1 2026 revenue of $389 million, exceeding analyst expectations of $236.36 million, while reaffirming guidance for up to 10% annual revenue growth. CEO Stéphane Bancel highlighted cost reductions and international sales growth, with $311 million from overseas COVID-19 vaccine demand compared to $78 million domestically. However, investors remain divided on whether the Hantavirus catalyst is sustainable, as early-stage vaccine programs rarely generate immediate revenue. Pfizer’s stock, in contrast, is less volatile due to its diversified pharmaceutical portfolio, including COVID-19 vaccines under the Comirnaty brand. The company reported adjusted earnings of $0.66 per share in Q4 2025 and maintains a 7% dividend yield, appealing to income-focused investors. Novavax, with a $1.69 billion market cap, remains highly sensitive to vaccine-related news, having faced boom-bust cycles tied to COVID-19 expectations. Its Q1 2026 results included a $30 million upfront payment from Pfizer for a Matrix-M adjuvant license, with up to $500 million in potential future milestones. Moderna’s next key catalyst is the August 5 FDA decision on its seasonal flu vaccine, mRNA-1010, which could become its fifth commercial product. Approval would expand its mRNA platform beyond COVID-19, potentially unlocking broader market opportunities. Analysts note that biotech sector rotation and technical breakouts are supporting Moderna’s recent gains, though long-term success hinges on translating research into commercial revenue streams.